2015 American Transplant Congress
Once-a-Day Administration of CNIs, mTOR and MMF Is Safe in De Novo Renal Transplant Recipients: 1-Year Results of a Pilot Study
Surgery - Renal Transplant Unit, Catholic University of the Sacred Heart, Rome, Italy.
Introduction. The half-lives of Tacrolimus, Everolimus, Cyclosporine and Mofetil Micofenolate (MMF) are respectively: 43, 30, 27 and 18 hours. Once-daily dosing of these drugs is…2015 American Transplant Congress
Acute Kidney Injury in the MELD Era of Liver Transplantation. Are Calcineurin Inhibitors So Problematic for Renal Function?
Acute kidney injury(AKI)after liver transplantation (LT) is common.Calcineurin inhibitors(CNI)have to be well-balanced.The aims were analyze the specific effect of CNI on AKI in a cohort…2015 American Transplant Congress
Intrapatient Variability of Tacrolimus Blood Concentrations Following Renal Transplant – Acute Rejection or No Connection?
Background: A high degree of intrapatient variability (IPV) of tacrolimus blood concentrations has been associated with poor long-term outcome (1). Periods of under-exposure with increased…2015 American Transplant Congress
Listing for Liver Transplantation of Patients With Hepatocellular Carcinoma Using the Extended Toronto Criteria; an Intention-to-Treat Analysis
Multi-Organ Transplant, Toronto General Hospital. University of Toronto, Toronto, ON, Canada.
The role of liver transplantation for patients whose HCC exceeds Milan criteria remains controversial. At the University of Toronto, we have reported survivals of a…2015 American Transplant Congress
An Analysis of Health-Related Quality of Life in Liver Transplantion for Hepatocellular Carcinoma
Vanderbilt Transplant Center, Vanderbilt University Medical Center, Nashville, TN.
Background:There is a disproportionate waiting time and an unclear survival benefit between hepatocellular carcinoma (HCC) versus non-HCC liver transplant recipients. However, there is paucity of…2015 American Transplant Congress
Pediatric Liver Transplantation: An Outcome Analysis of a 30-Year Single Center Experience
Introduction: In this study we aim to assess factors influencing long-term patient and graft survival as well as surgical parameters and risk factors influencing organ…2015 American Transplant Congress
Preemptive Rituximab Therapy of Epstein-Barr Virus (EBV) Infection to Prevent Post-Transplant Lymphoproliferative Disease (PTLD) After Pediatric Solid Organ Transplantation (SOT)
Purpose: More than 90% of pediatric PTLD after solid organ transplantation is associated with EBV infection. Reduction in immunosuppression is the first step to prevent…2015 American Transplant Congress
IL-2-Dependent Natural Killer Cell Responses to Epstein-Barr Virus B Cell Lymphomas Involve the NKG2A/NKG2C Axis
Stanford University School of Medicine, Stanford, CA.
Epstein Barr virus (EBV) infection elicits a strong host immune response that is considered to be essential for control of the virus and for preventing…2015 American Transplant Congress
T-Cell Immune Function Vs. Gene Expression Profiling for Heart Transplant Rejection
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: Non-invasive immune monitoring of heart transplant (HTx) patients (pts) is increasing in use. The AlloMap® blood test has proven helpful in surveillance of cardiac…2015 American Transplant Congress
Incidence and Characteristics of CMV Infection in High Risk (D+R-) Kidney Transplant Recipients and the Utility of Monthly Surveillance After Routine Prophylaxis
Internal Medicine, University of Pittsburgh, Pittsburgh, PA.
Cytomegalovirus (CMV) infection is the most common opportunistic viral infection after renal transplantation. Optimal duration of antiviral prophylaxis and the role of post prophylaxis surveillance…
- « Previous Page
- 1
- …
- 70
- 71
- 72
- 73
- 74
- …
- 170
- Next Page »